Role of the Wnt Signalling Pathway in Cancer

Abstract

Canonical Wnt/β‐catenin signalling is a highly conserved pathway that plays an essential role during embryonic development. In the adult, the Wnt pathway regulates stem cell maintenance and tissue homeostasis. Inappropriate activation of the Wnt signalling pathway has been implicated in a variety of cancers, most notably in colorectal cancer. Wnt signalling alterations in cancer have been identified at various levels of the pathway: at the membrane, in the cytoplasm and within the nucleus. Given that Wnt signalling plays a critical role in many human cancers, intense investigation has focused on targeting this pathway to develop potential therapeutics for cancer therapy.

Key Concepts

  • Wnt signalling is a highly conserved pathway in development.
  • A key role of the Wnt signalling pathway involves the maintenance of stem cell renewal.
  • Somatic mutations in the Wnt pathway components are commonly found in cancer, including over 90% of colorectal cancers.
  • Wnt pathway activation leads to inhibition of the β‐catenin destruction complex consisting of APC, Axin, CK1α and GSK3.
  • Mutations in the tumour suppressor, adenomatous polyposis coli (APC), lead to Wnt pathway activation.
  • Syndromes caused by germline mutations in Wnt pathway genes include familial adenomatous polyposis (FAP), which results in early polyp development and subsequent colorectal cancer.
  • Wnt pathway drugs have been developed to target receptor activation, β‐catenin degradation and nuclear activation, though currently none of these drugs are FDA approved for patient use.

Keywords: Wnt; cancer; small molecules; biologics; inhibitors; β‐catenin; Axin; APC; tumour suppressor; oncogene

Figure 1. Current model of Wnt signal transduction. Wnt components known to be altered in human cancers are shown in red. Wnt inhibitors are labelled in black. See main text for details.
close

References

Anastas JN and Moon RT (2013) WNT signalling pathways as therapeutic targets in cancer. Nature Reviews Cancer 13: 11–26. DOI: 10.1038/nrc3419.

Aoki K and Taketo MM (2007) Adenomatous polyposis coli (APC): a multi‐functional tumor suppressor gene. Journal of Cell Science 120: 3327–3335. DOI: 10.1242/jcs.03485.

Austinat M, Dunsch R, Wittekind C, et al. (2008) Correlation between β‐catenin mutations and expression of Wnt‐signaling target genes in hepatocellular carcinoma. Molecular Cancer 7: 21. DOI: 10.1186/1476-4598-7-21.

Barker N and Clevers H (2006) Mining the Wnt pathway for cancer therapeutics. Nature Reviews Drug Discovery 5: 997–1014. DOI: 10.1038/nrd2154.

Berge D ten Kurek D, Blauwkamp T, et al. (2011) Embryonic stem cells require Wnt proteins to prevent differentiation to epiblast stem cells. Nature Cell Biology 13: 1070–1075. DOI: 10.1038/ncb2314.

Berndt SI, Skibola CF, Joseph V, et al. (2013) Genome‐wide association study identifies multiple risk loci for chronic lymphocytic leukemia. Nature Genetics 45: 868–876. DOI: 10.1038/ng.2652.

Borcherding N, Kusner D, Kolb R, et al. (2015) Paracrine Wnt5A signaling inhibits expansion of tumor‐initiating cells. Cancer Research 75: 1972–1982. DOI: 10.1158/0008-5472.CAN-14-2761.

Cancer Genome Atlas Network (2012) Comprehensive molecular characterization of human colon and rectal cancer. Nature 487: 330–337. DOI: 10.1038/nature11252.

Dow LE, O'Rourke KP, Simon J, et al. (2015) Apc restoration promotes cellular differentiation and reestablishes crypt homeostasis in colorectal cancer. Cell 161: 1539–1552. DOI: 10.1016/j.cell.2015.05.033.

Emami KH, Nguyen C, Ma H, et al. (2004) A small molecule inhibitor of β‐catenin/CREB‐binding protein transcription [corrected]. Proceedings of the National Academy of Sciences of the United States of America 101: 12682–12687. DOI: 10.1073/pnas.0404875101.

Fearnhead NS, Britton MP and Bodmer WF (2001) The ABC of APC. Human Molecular Genetics 10: 721–733.

Giannakis M, Hodis E, Jasmine Mu X, et al. (2014) RNF43 is frequently mutated in colorectal and endometrial cancers. Nature Genetics 46: 1264–1266. DOI: 10.1038/ng.3127.

Gonsalves FC, Klein K, Carson BB, et al. (2011) An RNAi‐based chemical genetic screen identifies three small‐molecule inhibitors of the Wnt/wingless signaling pathway. Proceedings of the National Academy of Sciences of the United States of America 108: 5954–5963. DOI: 10.1073/pnas.1017496108.

Green JL, La J, Yum KW, et al. (2013) Paracrine Wnt signaling both promotes and inhibits human breast tumor growth. Proceedings of the National Academy of Sciences of the United States of America 110: 6991–6996. DOI: 10.1073/pnas.1303671110.

Gupta PB, Onder TT, Jiang G, et al. (2009) Identification of selective inhibitors of cancer stem cells by high‐throughput screening. Cell 138: 645–659. DOI: 10.1016/j.cell.2009.06.034.

Gurney A, Axelrod F, Bond CJ, et al. (2012) Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors. Proceedings of the National Academy of Sciences of the United States of America 109: 11717–11722. DOI: 10.1073/pnas.1120068109.

Herrera L, Kakati S, Gibas L, et al. (1986) Gardner syndrome in a man with an interstitial deletion of 5q. American Journal of Medical Genetics 25: 473–476. DOI: 10.1002/ajmg.1320250309.

Huang S‐MA, Mishina YM, Liu S, et al. (2009) Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 461: 614–620. DOI: 10.1038/nature08356.

Ilyas M, Tomlinson IP, Rowan A, et al. (1997) β‐catenin mutations in cell lines established from human colorectal cancers. Proceedings of the National Academy of Sciences of the United States of America 94: 10330–10334.

Jamieson CHM, Ailles LE, Dylla SJ, et al. (2004) Granulocyte‐macrophage progenitors as candidate leukemic stem cells in blast‐crisis CML. New England Journal of Medicine 351: 657–667. DOI: 10.1056/NEJMoa040258.

Jiang X, Hao H‐X, Growney JD, et al. (2013) Inactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinoma. Proceedings of the National Academy of Sciences of the United States of America 110: 12649–12654. DOI: 10.1073/pnas.1307218110.

Khan NI, Bradstock KF and Bendall LJ (2007) Activation of Wnt/?‐catenin pathway mediates growth and survival in B‐cell progenitor acute lymphoblastic leukaemia. British Journal of Haematology 138: 338–348. DOI: 10.1111/j.1365-2141.2007.06667.x.

Kim MS, Kim SS, Ahn CH, et al. (2009) Frameshift mutations of Wnt pathway genes AXIN2 and TCF7L2 in gastric carcinomas with high microsatellite instability. Human Pathology 40: 58–64. DOI: 10.1016/j.humpath.2008.06.006.

Kirstetter P, Anderson K, Porse BT, et al. (2006) Activation of the canonical Wnt pathway leads to loss of hematopoietic stem cell repopulation and multilineage differentiation block. Nature Immunology 7: 1048–1056. DOI: 10.1038/ni1381.

Korinek V, Barker N, Moerer P, et al. (1998) Depletion of epithelial stem‐cell compartments in the small intestine of mice lacking Tcf‐4. Nature Genetics 19: 379–383. DOI: 10.1038/1270.

la Roche M de Ibrahim AEK, Mieszczanek J and Bienz M (2014) LEF1 and B9L shield β‐catenin from inactivation by Axin, desensitizing colorectal cancer cells to tankyrase inhibitors. Cancer Research 74: 1495–1505. DOI: 10.1158/0008-5472.CAN-13-2682.

la Roche M de Rutherford TJ, Gupta D, et al. (2012) An intrinsically labile α‐helix abutting the BCL9‐binding site of β‐catenin is required for its inhibition by carnosic acid. Nature Communications 3: 680. DOI: 10.1038/ncomms1680.

Le PN, McDermott JD and Jimeno A (2015) Targeting the Wnt pathway in human cancers: therapeutic targeting with a focus on OMP‐54F28. Pharmacology & Therapeutics 146: 1–11. DOI: 10.1016/j.pharmthera.2014.08.005.

Li B, Flaveny CA, Giambelli C, et al. (2014) Repurposing the FDA‐approved pinworm drug pyrvinium as a novel chemotherapeutic agent for intestinal polyposis. PloS One 9: e101969. DOI: 10.1371/journal.pone.0101969.s003.

Liu J, Pan S, Hsieh MH, et al. (2013) Targeting Wnt‐driven cancer through the inhibition of Porcupine by LGK974. Proceedings of the National Academy of Sciences of the United States of America 110: 20224–20229. DOI: 10.1073/pnas.1314239110.

Mani M, Carrasco DE, Zhang Y, et al. (2009) BCL9 promotes tumor progression by conferring enhanced proliferative, metastatic, and angiogenic properties to cancer cells. Cancer Research 69: 7577–7586. DOI: 10.1158/0008-5472.CAN-09-0773.

Mazieres J, He B, You L, et al. (2004) Wnt inhibitory factor‐1 is silenced by promoter hypermethylation in human lung cancer. Cancer Research 64: 4717–4720. DOI: 10.1158/0008-5472.CAN-04-1389.

Morin PJ, Sparks AB, Korinek V, et al. (1997) Activation of β‐catenin‐Tcf signaling in colon cancer by mutations ina‐catenin or APC. Science 275: 1787–1790.

Muto Y, Maeda T, Suzuki K, et al. (2014) DNA methylation alterations of AXIN2 in serrated adenomas and colon carcinomas with microsatellite instability. BMC Cancer 14: 466. DOI: 10.1186/1471-2407-14-466.

Nusse R and Varmus HE (1982) Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell 31: 99–109.

Reya T and Clevers H (2005) Wnt signalling in stem cells and cancer. Nature 434: 843–850. DOI: 10.1038/nature03319.

Rijsewijk F, Schuermann M, Wagenaar E, et al. (1987) The Drosophila homolog of the mouse mammary oncogene int‐1 is identical to the segment polarity gene wingless. Cell 50: 649–657.

Roelink H, Wagenaar E, Lopes da Silva S and Nusse R (1990) Wnt‐3, a gene activated by proviral insertion in mouse mammary tumors, is homologous to int‐1/Wnt‐1 and is normally expressed in mouse embryos and adult brain. Proceedings of the National Academy of Sciences of the United States of America 87: 4519–4523.

Saito‐Diaz K, Chen TW, Wang X, et al. (2013) The way Wnt works: components and mechanism. Growth Factors 31: 1–31. DOI: 10.3109/08977194.2012.752737.

Satoh S, Daigo Y, Furukawa Y, et al. (2000) AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus‐mediated transfer of AXIN1. Nature Genetics 24: 245–250. DOI: 10.1038/73448.

Seshagiri S, Stawiski EW, Durinck S, et al. (2012) Recurrent R‐spondin fusions in colon cancer. Nature 488: 660–664. DOI: 10.1038/nature11282.

Shinmura K, Kahyo T, Kato H, et al. (2014) RSPO fusion transcripts in colorectal cancer in Japanese population. Molecular Biology Reports 41: 5375–5384. DOI: 10.1007/s11033-014-3409-x.

Su LK, Kinzler KW, Vogelstein B, et al. (1992) Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science 256: 668–670.

Suzuki H, Watkins DN, Jair K‐W, et al. (2004) Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nature Genetics 36: 417–422. DOI: 10.1038/ng1330.

Takada K, Zhu D, Bird GH, et al. (2012) Targeted disruption of the BCL9/‐catenin complex inhibits oncogenic Wnt signaling. Science Translational Medicine 4: 148ra117. DOI: 10.1126/scitranslmed.3003808.

Taniguchi H, Yamamoto H, Hirata T, et al. (2005) Frequent epigenetic inactivation of Wnt inhibitory factor‐1 in human gastrointestinal cancers. Oncogene 24: 7946–7952. DOI: 10.1038/sj.onc.1208910.

Tsukamoto AS, Grosschedl R, Guzman RC, et al. (1988) Expression of the int‐1 gene in transgenic mice is associated with mammary gland hyperplasia and adenocarcinomas in male and female mice. Cell 55: 619–625.

van de Wetering M, Francies HE, Francis JM, et al. (2015) Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell 161: 933–945. DOI: 10.1016/j.cell.2015.03.053.

Zhang Y, Liu S, Mickanin C, et al. (2011) RNF146 is a poly(ADP‐ribose)‐directed E3 ligase that regulates axin degradation and Wnt signalling. Nature Cell Biology 13: 623–629. DOI: 10.1038/ncb2222.

Zhang Y, Morris JP, Yan W, et al. (2013) Canonical Wnt signaling is required for pancreatic carcinogenesis. Cancer Research 73: 4909–4922. DOI: 10.1158/0008-5472.CAN-12-4384.

Further Reading

Anastas JN and Moon RT (2013) WNT signalling pathways as therapeutic targets in cancer. Nature Reviews Cancer 13: 11–26. DOI: 10.1038/nrc3419.

Clevers H, Loh KM and Nusse R (2014) Stem cell signaling. An integral program for tissue renewal and regeneration: Wnt signaling and stem cell control. Science 346: 1248012. DOI: 10.1126/science.1248012.

MacDonald BT, Tamai K and He X (2009) Wnt/beta‐catenin signaling: components, mechanisms, and diseases. Developmental Cell 17 (1): 9–26. DOI: 10.1016/j.devcel.2009.06.016.

Pinto D and Clevers H (2005) Wnt control of stem cells and differentiation in the intestinal epithelium. Experimental Cell Research 306 (2): 357–363. DOI: 10.1016/j.yexcr.2005.02.022.

Polakis P (2012) Drugging Wnt signalling in cancer. EMBO Journal 31 (12): 2737–2746. DOI: 10.1038/emboj.2012.126.

Contact Editor close
Submit a note to the editor about this article by filling in the form below.

* Required Field

How to Cite close
Baskir, Rubin S, Hansen, Amanda G, and Lee, Ethan(Apr 2016) Role of the Wnt Signalling Pathway in Cancer. In: eLS. John Wiley & Sons Ltd, Chichester. http://www.els.net [doi: 10.1002/9780470015902.a0025213]